A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
NeoplasmsMelanoma
Interventions
DRUG

Modakafusp Alfa

Modakafusp alfa intravenous infusion.

DRUG

Pembrolizumab

Pembrolizumab intravenous infusion.

Trial Locations (17)

3350

Ballarat Regional Integrated Cancer Center, Ballarat

5011

The Queen Elizabeth Hospital, Woodville South

15232

University of Pittsburgh Medical Center, Pittsburgh

26506

West Virginia University Health Sciences Campus, Morgantown

32806

Orlando Health Cancer Institute, Orlando

33136

Sylvester Comprehensive Cancer Center, Miami

37203

Sarah Cannon Research Institute, Nashville

44195

Cleveland Clinic Main Campus, Cleveland

57105

Avera Cancer Institute, Sioux Falls

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

80909

University of Colorado Health Memorial Hospital Central, Colorado Springs

84107

Intermountain Medical Center, Murray

90025

The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles

91010

City of Hope Comprehensive Cancer Center - Duarte, Duarte

92093

University of California San Diego Moores Cancer Center, La Jolla

03756

Norris Cotton Cancer Center Lebanon, Lebanon

07960

Morristown Medical Center, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04157517 - A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter